Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome

Circulation: Cardiovascular Interventions

Volumn 7, Issue 1, 2014, Pages 104-112

  Caiazzo, Gianluca ^a   De Rosa, Salvatore ^a   Torella, Daniele ^a   Spaccarotella, Carmen ^a   Mongiardo, Annalisa ^a   Giampà, Salvatore ^a   Micieli, Mariella ^a   Palella, Eleonora ^b   Gulletta, Elio ^b   Indolfi, Ciro ^a,c  

^a Division of Cardiology Department of Medical and Surgical Sciences   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c CNR   (Italy)

Author keywords

Acute coronary syndrome; Platelet aggregation; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADULT; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECCHYMOSIS; ELECTRODE; EPISTAXIS; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEART MUSCLE REVASCULARIZATION; HEMATURIA; HEMORRHOID; HUMAN; LOADING DRUG DOSE; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE CORONARY SYNDROME; PLATELET AGGREGATION; TICAGRELOR;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; DRUG DOSAGE CALCULATIONS; DRUG SUBSTITUTION; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84900386395     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.113.000512     Document Type: Article

References (18)

1. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub WS. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention. results from the clopidogrel for the reduction of events during observation (CREDO) trial. J Am Coll Cardiol. 2005;46:761-769.
2. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
3. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
4. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999-3054.
5. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569-2619.
6. Cirillo P, Golino P, Calabro P, Ragni M, Forte L, Piro O, De Rosa S, Pacileo M, Chiariello M. Activated platelets stimulate tissue factor expression in smooth muscle cells. Thromb Res. 2003;112:51-57.
7. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736-2747.
8. Teixeira R, Monteiro P, Marques G, Pego JM, Lourenco M, Tavares C, Reboredo A, Monteiro S, Goncalves F, Ferreira MJ, Freitas M, Ribeiro G, Providencia LA. Platelet aggregation at discharge: a useful tool in acute coronary syndromes? Rev Port Cardiol. 2012;31:545-554.
9. Nuhrenberg TG, Trenk D, Leggewie S, Ristau I, Amann M, Stratz C, Hochholzer W, Valina CM, Neumann FJ. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Platelets. 2013;24:549-553.
10. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schomig A, von Beckerath N, Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost. 2010;8:250-256.
11. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, Lopez-Sendon J, Lassila R, Mahaffey KW, Storey RF, Harrington RA, Wallentin L. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011;32:2933-2944.
12. Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Effron MB; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56:1017-1023.
13. Lhermusier T, Voisin S, Mejean S, Garcia C, Sié P, Carrié D. Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. J Thromb Haemost. 2012;10:1946-1949.
14. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P; ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369:999-1010.
15. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215-1223.
16. Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856.
17. Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J. 2008;29:2877-2885.
18. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50:1822-1834.